Published Online: Wednesday, November 1, 2006

The nomination of Andrew von Eschenbach, MD, to serve as commissioner of the FDA drew a solid thumbs-up from generic drug industry leaders, who are hopeful that permanent leadership at the agency will result in more focus on cost-saving generic pharmaceuticals.

"As an agency whose mission it is to protect the public health, [the FDA] needs a leader at the helm," Generic Pharmaceutical Association President Kathleen Jaeger said. "The FDA has many critical issues on its plate that impact consumers' ability to obtain safe, effective, and affordable generic medicines, such as establishing an abbreviated approval pathway for generic biopharmaceuticals and ensuring increased funding for the Office of Generic Drugs."

Latest Articles
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Latest Issues